Accession Number : ADP008542
Title : Prevention of Reocclusion by a Thrombin Inhibitor,
Corporate Author : LILLY (ELI) AND CO INDIANAPOLIS IN LILLY RESEARCH LABS
Personal Author(s) : Shuman, Robert T. ; Rothenberger, Robert B. ; Campbell, Charles S. ; Smith, Gerald F. ; Jackson, Charles V.
Report Date : 1992
Pagination or Media Count : 2
Abstract : Arterial reocclusion after successful coronary thrombolysis therapy remains a significant problem in the management of heart disease. It was demonstrated that opening of the coronary artery with thrombolytic therapy may reduce the death rate in patients with acute myocardial infarction. The beneficial effect is more dramatic if blood flow is restored early and is persistent. However, pharmacologically induced thrombolysis, which exposes a highly thrombogenic substance (the residual clot) to the circulation may lead to rethrombosis, and reinfarction. It is known that reocclusion or rethrombosis occurs in 20 to 30% of patients who undergo successful thrombolysis with tissue-type plasminogen activator (t-PA). Therefore, many patients need adequate antithrombotic treatment. Currently, heparin is used to maintain coronary artery flow to prevent reocclusion. However, heparin was found to be ineffective in preventing reocclusion. Other therapeutic agents were investigated to accelerate early vessel patency and prevent reocclusion. These agents include thrombin inhibitors due to the key role thrombin plays in the blood coagulation cascade. We have studied the effects of LY282056 (a potent thrombin inhibitor) in animal models that correlate with arterial thrombosis in humans.
Descriptors : *ENZYME INHIBITORS, *THROMBIN, *ANTICOAGULANTS, CORONARY ARTERIES, THROMBOSIS, CORONARY DISEASE, MYOCARDIAL INFARCTION.
Subject Categories : Pharmacology
Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE